Citations

Mayo Clinic

Showing 10 of 108551 citations.

The natural history of aneurysms incompletely occluded by placement of a flow diverter: a multiinstitutional study
Theiss, Peter , Ali, Ahmed Essam, McGuire, Laura Stone , Brinjikji, Waleed , Naamani, Kareem El, Amllay, Abdelaziz , Tjoumakaris, Stavropoula , Jabbour, Pascal , Salem, Mohamed M. , Burkhardt, Jan‐Karl , Jankowitz, Brian T. , Abla, Adib A. , Kan, Peter , Alaraj, Ali , Alaraj, Ali , Abla, Adib , Burkhardt, Jan‐Karl , Lanzino, Giuseppe , Ghozy, Sherief , Naamani, Kareem El , Jabbour, Pascal , Tonetti, Daniel A. , Robledo, Ariadna

Journal of Neurosurgery | March 8, 2024 | Volume: 141 | Issue: 2 | Pages: 310-315

10.3171/2023.12.jns232221 | PMID 38457799 Get It

OBJECTIVE Treatment of intracranial aneurysms by flow diversion is safe and effective and is increasingly popular. However, the correct treatment paradigm for aneurysms incompletely treated by initial placement of a flow diverter has not been established, nor have the subsequent natural history and occlusion rates of such aneurysms. The authors sought to outline the natural history of such aneurysms, which to date have been considered partially treated. METHODS The authors retrospectively reviewed consecutive cases from 6 high-volume neurointerventional services, including all cases in which the first follow-up imaging after placement of a flow diverter showed incomplete occlusion of the aneurysm, and for which subsequent clinical and/or radiological follow-up was available. All included patients were treated with the Pipeline Flex embolization device or the Pipeline Flex embolization device with Shield Technology. Subsequent radiographic and clinical outcome data were collected and analyzed using the Kaplan-Meier survival function. RESULTS A total of 263 patients with persistently patent aneurysms on first follow-up imaging after flow diversion were identified. Of these, 204 had clinical follow-up and 152 had additional imaging follow-up. Of this final cohort, 148 aneurysms were unruptured, and 4 were ruptured. The average aneurysm size by maximum dimension was 10.8 mm. The average recorded follow-up was 27.8 months in the cohort, with some patients followed for as long as 9 years from treatment. Over the course of 403 person-years of follow-up, no delayed aneurysm ruptures were recorded. Both with and without retreatment, aneurysms showed a trend toward progressive occlusion over time. Complications related to device placement were low. CONCLUSIONS Aneurysms that have been incompletely treated by flow diversion have a benign natural history with progression toward occlusion over time, with or without retreatment.
IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation
Hong, Lih En , Wechalekar, Mihir D. , Small, Annabelle , Lim, Kelly , Thompson-Peach, Chloe , Li, Joule J., Chhetri, Rakchha , Scott, Hamish S. , Brown, Anna , Hahn, Christopher N , Sajid, Salvia , Robinson, Nirmal , Thomas, Ranjeny , Branford, Susan , D’Andrea, Richard J. , Samaraweera, Saumya E. , Patnaik, Mrinal M. , Hiwase, Devendra , Small, Annabelle , Lim, Kelly , Thompson-Peach, Chloe , Scott, Hamish , Brown, Anna L , Hahn, Christopher , Sajid, Salvia , Robinson, Nirmal , Branford, Susan , D'Andrea, Richard J , Samaraweera, Saumya E , Patnaik, Mrinal , Proudman, Susanna , Kok, Chung H , Shah, Mithun V , Hiwase, Devendra , Kutyna, Monika , Yeung, David , THOMAS, DANIEL W. , Kok, Chung Hoow , Shah, Meera

Blood | March 8, 2024 | Volume: 143 | Issue: 18 | Pages: 1873-1877

10.1182/blood.2023023593 | PMID 38457663 Get It

Abstract High prevalence of IDH mutations in seronegative rheumatoid arthritis (RA) with myeloid neoplasm, elevated 2-hydroxyglutarate, dysregulated innate immunity, and proinflammatory microenvironment suggests causative association between IDH mutations and seronegative RA. Our findings merit investigation of IDH inhibitors as therapeutics for seronegative IDH-mutated RA.
Professional Employment With Left Ventricular Assist Device Support: Does Working With an LVAD Allow It to Work Too?
Inglis, Sara S. , Rosenbaum, Andrew , Rosenbaum, Andrew N , Inglis, Sara S

ASAIO Journal | March 8, 2024 | Volume: 70 | Issue: 5 | Pages: 356-357

10.1097/mat.0000000000002187 | PMID 38457524 Get It

MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231
Hayashi, Robert J. , Hermiston, Michelle L. , Wood, Brent L. , Teachey, David T. , Devidas, Meenakshi , Chen, Zhiguo , Annett, Robert D. , Asselin, Barbara L. , August, Keith J. , Cho, Steve , Galardy, Paul J. , Harker‐Murray, Paul , Jaju, Alok , Lam, Allison, Miles, Rodney R., Okada, Maki , Patel, Samir , Schechter, Tal , Shimano, Kristin A. , Singh, Neelam, Steele, Amii C., Sulis, Maria Luisa , Vargas, Sarah , Winter, Stuart S. , Wood, Charlotte, Loh, Mignon L. , Raetz, Elizabeth A. , Bollard, Catherine M. , Allen, Carl E. , August, Keith , Freedman, Jason Lawrence , Galardy, Paul J , Harker-Murray, Paul , Horton, Terzah M. , Jaju, Alok I , Messinger, Yoav H , Okada, Maki , Schafer, Eric S , Shimano, Kristin A , Sulis, Maria L , Winter, Stuart S , Zweidler-McKay, Patrick A , Loh, Mignon L , Hunger, Stephen P , Raetz, Elizabeth A , Bollard, Catherine M , Allen, Carl E , Wood, Brent L , Devidas, Meenakshi , Dunsmore, Kimberly P , Messinger, Yoav H. , Schafer, Eric S. , Hunger, Stephen P.

Blood | March 8, 2024 | Volume: 143 | Issue: 20 | Pages: 2053-2058

10.1182/blood.2023021184 | PMID 38457359 Get It

Abstract Defining prognostic variables in T-lymphoblastic lymphoma (T-LL) remains a challenge. AALL1231 was a Children’s Oncology Group phase 3 clinical trial for newly diagnosed patients with T acute lymphoblastic leukemia or T-LL, randomizing children and young adults to a modified augmented Berlin-Frankfurt-Münster backbone to receive standard therapy (arm A) or with addition of bortezomib (arm B). Optional bone marrow samples to assess minimal residual disease (MRD) at the end of induction (EOI) were collected in T-LL analyzed to assess the correlation of MRD at the EOI to event-free survival (EFS). Eighty-six (41%) of the 209 patients with T-LL accrued to this trial submitted samples for MRD assessment. Patients with MRD <0.1% (n = 75) at EOI had a superior 4-year EFS vs those with MRD ≥0.1% (n = 11) (89.0% ± 4.4% vs 63.6% ± 17.2%; P = .025). Overall survival did not significantly differ between the 2 groups. Cox regression for EFS using arm A as a reference demonstrated that MRD EOI ≥0.1% was associated with a greater risk of inferior outcome (hazard ratio, 3.73; 95% confidence interval, 1.12-12.40; P = .032), which was independent of treatment arm assignment. Consideration to incorporate MRD at EOI into future trials will help establish its value in defining risk groups. CT# NCT02112916.
Defective transfer of parental histone decreases frequency of homologous recombination by increasing free histone pools in budding yeast
Karri, Srinivasu , Yang, Yi , Dickinson, Quinn , Jia, Jing , Huang, Yuxin , Wang, Zhiquan , Gan, Haiyun , Yu, Chuanhe , Yu, Chuanhe , Zhou, Jiaqi , Wang, Zhiquan

Nucleic Acids Research | March 8, 2024 | Volume: 52 | Issue: 9 | Pages: 5138-5151

10.1093/nar/gkae205 | PMID 38554108 Get It

Abstract Recycling of parental histones is an important step in epigenetic inheritance. During DNA replication, DNA polymerase epsilon subunit DPB3/DPB4 and DNA replication helicase subunit MCM2 are involved in the transfer of parental histones to the leading and lagging strands, respectively. Single Dpb3 deletion (dpb3Δ) or Mcm2 mutation (mcm2-3A), which each disrupts one parental histone transfer pathway, leads to the other's predominance. However, the biological impact of the two histone transfer pathways on chromatin structure and DNA repair remains elusive. In this study, we used budding yeast Saccharomyces cerevisiae to determine the genetic and epigenetic outcomes from disruption of parental histone H3–H4 tetramer transfer. We found that a dpb3Δ mcm2-3A double mutant did not exhibit the asymmetric parental histone patterns caused by a single dpb3Δ or mcm2-3A mutation, suggesting that the processes by which parental histones are transferred to the leading and lagging strands are independent. Surprisingly, the frequency of homologous recombination was significantly lower in dpb3Δ, mcm2-3A and dpb3Δ mcm2-3A mutants, likely due to the elevated levels of free histones detected in the mutant cells. Together, these findings indicate that proper transfer of parental histones during DNA replication is essential for maintaining chromatin structure and that lower homologous recombination activity due to parental histone transfer defects is detrimental to cells.
The pandemic in retrospect: Sigmund Freud and Spanish influenza
Ganguly, Amvrine

Industrial Psychiatry Journal | March 8, 2024 | Volume: 33 | Issue: Suppl 1 | Pages: S274-S275

10.4103/ipj.ipj_300_23 | PMID 39534162 Get It

Sleep-related painful erections treated with sodium oxybate
Chaudhary, Hira, Zeidman, Eric J., Tashman, Yasemin, Chaudhary, Hira S, Zeidman, Eric, Punjani, Nahid

Journal of Clinical Sleep Medicine | March 8, 2024 | Volume: 20 | Issue: 7 | Pages: 1209-1211

10.5664/jcsm.11120 | PMID 38456812 Get It

Addressing Patient Concerns with Blood Transfusion from Donors Vaccinated Against COVID-19: A Clinician Primer
Forkin, Katherine T. , Guinn, Nicole R. , Warner, Matthew A. , Panigrahi, Anil K. , Warner, Matthew A

Anesthesiology | March 8, 2024 | Volume: 140 | Issue: 5 | Pages: 1020-1025

10.1097/aln.0000000000004913 | PMID 38457190 Get It

Need for a Cardiogenic Shock Team Collaborative—Promoting a Team‐Based Model of Care to Improve Outcomes and Identify Best Practices
Senman, Balimkiz , Jentzer, Jacob C. , Barnett, Christopher F. , Bartos, Jason A. , Berg, David D. , Chih, Sharon , Drakos, Stavros G. , Dudzinski, David M. , Elliott, Andrea , Horowitz, James M. , Miller, P. Elliott , Tehrani, Behnam , Vallabhajosyula, Saraschandra , Katz, Jason N. , Horowitz, James M , Miller, P Elliott , Sinha, Shashank S , Yuriditsky, Eugene , Vallabhajosyula, Saraschandra , Katz, Jason N , Jentzer, Jacob C , Berg, David , Gage, Ann

Journal of the American Heart Association | March 8, 2024 | Volume: 13 | Issue: 6 | Pages: No page available

10.1161/jaha.123.031979 | PMID 38456417 Get It

Cardiogenic shock continues to carry a high mortality rate despite contemporary care, with no breakthrough therapies shown to improve survival over the past few decades. It is a time‐sensitive condition that commonly results in cardiovascular complications and multisystem organ failure, necessitating multidisciplinary expertise. Managing patients with cardiogenic shock remains challenging even in well‐resourced settings, and an important subgroup of patients may require cardiac replacement therapy. As a result, the idea of leveraging the collective cognitive and procedural proficiencies of multiple providers in a collaborative, team‐based approach to care (the “shock team”) has been advocated by professional societies and implemented at select high‐volume clinical centers. A slowly maturing evidence base has suggested that cardiogenic shock teams may improve patient outcomes. Although several registries exist that are beginning to inform care, particularly around therapeutic strategies of pharmacologic and mechanical circulatory support, none of these are currently focused on the shock team approach, multispecialty partnership, education, or process improvement. We propose the creation of a Cardiogenic Shock Team Collaborative—akin to the successful Pulmonary Embolism Response Team Consortium—with a goal to promote sharing of care protocols, education of stakeholders, and discovery of how process and performance may influence patient outcomes, quality, resource consumption, and costs of care.
Proton versus photon craniospinal irradiation for adult medulloblastoma: A dosimetric, toxicity, and exploratory cost analysis
Breen, William G. , Geno, Connie, Waddle, Mark R. , Harmsen, William S. , Sener, Uğur , Ruff, Michael W. , Neth, Bryan J. , Uhm, Joon H. , Yan, Elizabeth , Kruse, Jon J. , Brown, Paul D. , Mahajan, Anita , Geno, Connie S, Qian, Jing , Sener, Ugur T, Neth, Byran J. , Sener, Ugur , Qian, Jing, Burns, Terry C. , Routman, David M. , Laack, Nadia N.

Neuro-Oncology Advances | March 8, 2024 | Volume: 6 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdae034 | PMID 38550393 Get It

Abstract Background This study aimed to determine whether proton craniospinal irradiation (CSI) decreased the dose to normal tissue and resulted in less toxicity than photon CSI for adult patients. Methods This single-institution retrospective analyzed differences in radiation doses, acute toxicity, and cost between proton and CSI for adult medulloblastoma patients. Results Of 39 total patients, 20 were treated with photon CSI prior to 2015, and 19 were treated with proton CSI thereafter. Median age was 28 years (range 18–66). The molecular subtype was most commonly sonic hedgehog (68%). Patients most commonly received 36 Gy CSI in 20 fractions with a boost to 54–55.8 Gy (92%). Proton CSI delivered significantly lower mean doses to cochleae, lacrimal glands, lens, parotid glands, pharyngeal constrictors, esophagus, lungs, liver, and skin (all P < .001). Patients receiving proton CSI had significantly lower rates of acute dysphagia of any grade (5% versus 35%, P = .044) and decreased median weight loss during radiation (+1.0 versus –2.8 kg, P = .011). Weight loss was associated with acute hospitalization (P = .009). Median follow-up was 2.9 and 12.9 years for proton and photon patients, respectively, limiting late toxicity and outcome comparisons. At the last follow-up, 5 photon patients had died (2 of progressive disease, 3 without recurrence ages 41–63) and 21% had experienced major cardiovascular events. At 10 years, 89% were alive and 82% were recurrence free. Conclusions This study demonstrates dosimetric improvements with proton CSI, potentially leading to decreased acute toxicity including dysphagia and weight loss during treatment.